Elto update has me digging for clues - someone, ma
Post# of 30027
(Total Views: 411)
Posted On: 02/19/2022 7:50:29 PM
.jpg)
Elto update has me digging for clues - someone, maybe maui always maintained Coeptis was still in the picture... he may be right
1. New website: https://coeptistx.com/ a reminder that Coeptis has links to Amarantus through its Pennsylvania base, and Karolinksa Institute/other baltic science backgrounds. It formed a Scientific Advisory Board straight from Karolinksa in Jan 2022. Researchers from Karolinksa led the Eltoprazine phase 2a trial back in the day https://news.ki.se/new-therapeutic-principle-...cal-effect
2. Coeptis ($COEP) has a $185M market cap and completed it's reorganization as the surviving entity of a merger with vining holdings this past summer. It has a couple million in cash as of Q3/2021
3. Back in 2018, when Coeptis was announced to acquire Elto, concensi was it's only asset. That was terminated/didn't work out. Then they tried some other things, including a del with Purple Biotech from, you guessed it, Rehovot Israel. That also didn't work out. Now it's a partner with Vygen and others.
4. Company states: "Following the reverse merger transaction involving us and Coeptis, we continue to focus on identifying and investing resources into innovative products and technologies which we believe will significantly transform Coeptis’ current products and therapies." They appear to be in aggressive expansion mode.
As a reminder, an independent third-party valuation valued eltoprazine in the U.S. and Europe at $316 million in 2018.
1. New website: https://coeptistx.com/ a reminder that Coeptis has links to Amarantus through its Pennsylvania base, and Karolinksa Institute/other baltic science backgrounds. It formed a Scientific Advisory Board straight from Karolinksa in Jan 2022. Researchers from Karolinksa led the Eltoprazine phase 2a trial back in the day https://news.ki.se/new-therapeutic-principle-...cal-effect
2. Coeptis ($COEP) has a $185M market cap and completed it's reorganization as the surviving entity of a merger with vining holdings this past summer. It has a couple million in cash as of Q3/2021
3. Back in 2018, when Coeptis was announced to acquire Elto, concensi was it's only asset. That was terminated/didn't work out. Then they tried some other things, including a del with Purple Biotech from, you guessed it, Rehovot Israel. That also didn't work out. Now it's a partner with Vygen and others.
4. Company states: "Following the reverse merger transaction involving us and Coeptis, we continue to focus on identifying and investing resources into innovative products and technologies which we believe will significantly transform Coeptis’ current products and therapies." They appear to be in aggressive expansion mode.
As a reminder, an independent third-party valuation valued eltoprazine in the U.S. and Europe at $316 million in 2018.
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼